Generex Biotechnology CEO Joe Moscato To Present at H.C. Wainwright Healthcare Conference
9:00 AM ET, 06/04/2019 - GlobeNewswire
H.C. WAINWRIGHT 21st ANNUAL GLOBAL INVESTMENT CONFERENCEThe Lotte New York Palace Hotel, New York, NYSeptember 8 – 10, 2019
MIRAMAR, Fla., June 04, 2019 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that Joe Moscato, the company’s Chief Executive Officer and his team of seasoned industry leaders are scheduled to present at the H.C. Wainwright Global Investor Conference to be held in New York from September 8 to 10. Mr. Moscato will present the Generex corporate strategy and operating results and will be meeting with leading healthcare investors to present the corporate vision for Generex Biotechnology as an integrated healthcare holding company with a unique strategy to provide end-to-end, patient centric solutions to enhance the doctor patient relationship.
“We are proud and honored to be asked to present the “New” Generex at the H.C. Wainwright conference,” stated Joe Moscato, CEO of Generex. “H.C. Wainwright is the preeminent, number one investment banking healthcare firm. They are a force in the biotech investment community, and we look forward to the opportunity to present our vision to their investors.”
About Generex Biotechnology Corp.Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.
In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization, a network of pharmacies, clinical laboratory, and medical device companies with new and approved products.
Our newly formed, wholly-owned subsidiary, NuGenerex Distribution Solutions (NDS), integrates our MSO network with a pharmacy network, clinical diagnostic lab, durable medical equipment company (DME-IQ) and dedicated call center.
Cautionary Note Regarding Forward-Looking Statements
9:00 AM ET, 06/04/2019 - GlobeNewswire
H.C. WAINWRIGHT 21st ANNUAL GLOBAL INVESTMENT CONFERENCEThe Lotte New York Palace Hotel, New York, NYSeptember 8 – 10, 2019
MIRAMAR, Fla., June 04, 2019 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that Joe Moscato, the company’s Chief Executive Officer and his team of seasoned industry leaders are scheduled to present at the H.C. Wainwright Global Investor Conference to be held in New York from September 8 to 10. Mr. Moscato will present the Generex corporate strategy and operating results and will be meeting with leading healthcare investors to present the corporate vision for Generex Biotechnology as an integrated healthcare holding company with a unique strategy to provide end-to-end, patient centric solutions to enhance the doctor patient relationship.
“We are proud and honored to be asked to present the “New” Generex at the H.C. Wainwright conference,” stated Joe Moscato, CEO of Generex. “H.C. Wainwright is the preeminent, number one investment banking healthcare firm. They are a force in the biotech investment community, and we look forward to the opportunity to present our vision to their investors.”
About Generex Biotechnology Corp.Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.
In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization, a network of pharmacies, clinical laboratory, and medical device companies with new and approved products.
Our newly formed, wholly-owned subsidiary, NuGenerex Distribution Solutions (NDS), integrates our MSO network with a pharmacy network, clinical diagnostic lab, durable medical equipment company (DME-IQ) and dedicated call center.
Cautionary Note Regarding Forward-Looking Statements
